報價延遲最少15分鐘:2026/04/21 19:45 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.9492 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.32/-0.13
|
|
企業價值
45.38M
|
| 資產負債 |
|
每股賬面淨值
0.12
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.12M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. |
